Vaccines Market Gaining Traction from Governmental Immunization Programs

The upsurge in the prevalence of infectious diseases such as polio, measles, and viral hepatitis caused by fungi and bacteria can be significantly curtailed by providing proper vaccination, which also ensures maintaining sustainable health throughout the lifetime. Vaccinations play a major role to strengthen the immune system during the lifespan of an individual. Growing focus of people and government initiatives on immunization programs for safe and secure life and production of technologically advanced vaccines will drive the growth of vaccines the market, according to the analyst of a recent business intelligence study from IndustryARC. The report evaluates the global vaccines market size to be around $33 billion to $36 billion as of 2018, and projects the opportunities to grow at a CAGR of around 8% to 10% during the forecast period 2019 to 2025. The IndustryARC report is titled as “Vaccines Market: By Type (Monovalent, Multivalent); By Technology (Conjugate Vaccines, Inactivated and Subunit Vaccines, Others); By Disease Indication (Pneumococcal Disease, DTP, Others); By End User (Paediatrics, Adults) & Region – Forecast (2019 - 2025).”

The analyst of the report identifies that North America held the major share in the vaccines market and was around 34% to 36%.  North America’s dominance is due the robust healthcare infrastructure in the U.S. and Canada as well as the presence of a number of research and development facilities. Moreover, the major demand share in this region is also ascribed to deep-rooted vaccination programs, growing pervasiveness of diseases, and embracing adoptions of progressive vaccines. According to Immunization 317 Coalition in USA, increasing the federal funding for disease control and prevention is paramount. Section 317 provides a safety programs for underinsured adult’s population who have no other alternative to recompenses for vaccination.

Inactivated vaccines are the key application in the vaccines market as per the new findings of the IndustryARC, and this application is projected to grow at a CAGR of around 8% to 9% during the forecast period of 2019 to 2025. Growing usage of inactivated vaccines to protect against various diseases such as flu, rabies, and polio will propel the growth of the market. According to The United Nations International Children's Emergency Fund, the need for the inactivated polio vaccines for immunization is 65 million doses. On the other hand, the availability of prequalified inactivated polio vaccines in 2019 is 71 million doses, out of which 64 million are essential for immunization needs. This availability of the inactivated vaccines for the prevention of various diseases will fuel the vaccines market in the near future.

Escalating demand for vaccine delivery systems such as micellar delivery systems, polymeric nanoparticle delivery systems, emulsion-type vaccine delivery systems, liposomal delivery systems, and immune-simulating complexes (ISCOMs), and needle-free technologies are developed to induce vaccines into human body through different routes. These delivery systems will enable the reduction in the number of doses of vaccine at the injection site. Moreover, microscopic nanoparticles acts as the transport mechanism for antigens in order to deliver them directly to immune cells.

The innovative Multiple Antigen Presenting System (MAPS) modular method enables the efficient production of vaccines which offers robust immunological and technical advantages. Additionally this method develops vaccines for pathogens including pneumococcus and tuberculosis for strong immune response in our body. 

Emergent BioSolutions Completes Acquisition with PaxVax to advance the pipeline with vaccines in order to address acute respiratory diseases and viral spread disease chikungunya. This acquisition resulted in the development and manufacturing of specialty vaccines such as Vivotif oral vaccine and Vaxchora for the prevention of emerging infectious diseases.

Some of the key players operating in vaccines market are: Merck &Co., Inc., Emergent Bio Solutions, Inc., Johnson and Johnson, Sanofi Pasteur, Inc., Pfizer, Inc., Novartis AG, CSL Ltd., GlaxoSmithKline Plc, Abbott Laboratories, Inc., AstraZeneca Plc, Janssen Pharmaceuticals, Inc

Therapeutic Vaccine Market: By Vaccine Type (Addiction, Neurological, Infectious, Autoimmune); By Technology (Autologous, Allogenic) & By region - Forecast(2018 - 2023)

DNA Vaccines Market: By Type (DNA vaccines for humans & DNA vaccines for animals), By Therapeutic Category (Oncology, Infectious Diseases, Neurology & Others) & By Region - Forecast(2018 - 2023)